Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium versus Quetiapine in Treatment Resistant Depression (LQD)
NCT03004521Phase 4Unknown
- Sponsor
- King's College London
- Start
- Nov 2016
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in major depressive disorder (MDD) comparing Lithium Arm with Quetiapine Arm (2 arms). Primary endpoints: Quick Inventory of Depressive Symptomatology (Self-Report) at 52 weeks and Time to all-cause treatment discontinuation at 12 months. Status: unknown.
02
Drugs
quetiapinelithium
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03004521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004521.